Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Valeant Dumps Another Asset in Cash Deal

Valeant Pharmaceuticals is selling its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund I for $190 million in cash.

Read More »

How AstraZeneca’s Silence Led to a $4 Billion Loss Overnight

As rumors swirled about whether or not AstraZeneca Chief Executive Officer Pascal Soriot was leaving for Israel-based Teva Pharmaceutical, investors expressed their concerns with a sell off that cost the British company $4 billion overnight.

Read More »

FDA Gives Nod to J&J’s Tremfya

FDA approved Janssen Biotech’s Tremfya (guselkumab) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Read More »

San Diego’s Arena Soars as Phase II Hypertension Trial Data Wows

San Diego-based Arena Pharmaceuticals’ shares rocketed after positive data was announced from its Phase II clinical trial of a drug for pulmonary arterial hypertension (PAH).

Read More »

Robot wars: knee surgery marks new battleground for companies

The world’s top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied.

Read More »

Oxford BioMedica wins big contract for Novartis cell therapy

Novartis signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.

Read More »

Opdivo Prevails in Phase III Melanoma Trial

Bristol-Myers Squibb announced promising interim data from its Phase III clinical trial of Opdivo 3 mg/kg compared to 10 mg/kg Yervoy in melanoma.

Read More »

AstraZeneca cancer drug trial prompts investors to take options cover

Investors in drugmaker AstraZeneca have taken defensive positions in the options market ahead of eagerly awaited results of a major trial of a lung cancer treatment.

Read More »

FDA Approves First Anticoagulant for Hospitals

Portola Pharmaceuticals announced that the U.S. Food and Drug Administration approved the potential blockbuster drug Bevyxxa (betrixaban).

Read More »

New Roche hemophilia drug prevents bleeds

The investigational hemophilia drug emicizumab cut the bleed rate by 87% in patients with resistance to standard therapy versus those receiving another treatment.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom